Welcome to our dedicated page for DexCom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on DexCom stock.
DexCom, Inc. (DXCM) is a leading medical device company founded in 1999, specializing in continuous glucose monitoring (CGM) systems. These systems provide a significant advancement over traditional blood glucose meters, offering real-time glucose readings for diabetic patients. DexCom's innovative CGM technology empowers patients and clinicians to better manage diabetes, contributing to improved health outcomes.
DexCom's flagship products include the Dexcom G6 and the newly developed Dexcom G7 CGM systems. These devices offer features such as customizable alerts, seamless app integration, and data sharing capabilities. The company is also working on integrating their CGM systems with insulin pumps from Insulet and Tandem Diabetes Care, Inc., enabling automatic insulin delivery for more efficient diabetes management.
Recent achievements include the expansion into international markets and the continuous enhancement of their product lineup through research and development. Financially, DexCom has shown robust growth with increasing revenues and solid market performance, reflecting the growing demand for advanced diabetes management solutions.
The company has established strategic partnerships with key players in the medical device industry, further enhancing their market presence and technological capabilities. DexCom is committed to innovation, patient empowerment, and improving the quality of life for people with diabetes worldwide.
Rhea-AI Summary
DexCom, Inc. (Nasdaq: DXCM) reported strong financial results for the fourth quarter and fiscal year ended December 31, 2023. Revenue grew 27% to $1.03 billion in the fourth quarter and 24% to $3.62 billion for the full year. The company also achieved significant operating income and net income growth. Strategic highlights include the submission of Dexcom's new glucose sensor for people with type 2 diabetes to the FDA for review and partnerships with Tandem Diabetes Care and Beta Bionics for insulin pump connectivity. The company has reiterated its fiscal year 2024 guidance with expected revenue of approximately $4.15 - 4.35 billion and non-GAAP operating margin of approximately 20%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.18%
Tags
-
News
Rhea-AI Summary
Dexcom, Inc. (Nasdaq: DXCM) has launched its latest continuous glucose monitoring (CGM) system, Dexcom ONE+, in Spain, Belgium, and Poland, with the Netherlands launching next week. The system is designed to make it easier for people with Type 1 and Type 2 diabetes to manage their condition and see their glucose readings without painful fingerpricks. Dexcom ONE+ incorporates user and healthcare professional feedback, offering personalization, flexibility, and the highest waterproof rating when compared to other CGM brands.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.04%
Tags
-
Rhea-AI Summary
DexCom, Inc. (DXCM) plans to release its Q4 and FY 2023 financial results on February 8, 2024, followed by a conference call to review performance. The call will be webcast and archived on the investor relations website. Dial-in details are provided for listening to the conference call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
Rhea-AI Summary
Dexcom, Inc. (Nasdaq: DXCM) has broken ground on its new state-of-the-art manufacturing facility in Athenry, Co. Galway, creating over 1,000 jobs and representing one of the biggest single private sector investments in the West of Ireland. The facility will produce millions of Dexcom rtCGM sensors annually, helping improve the lives of people with diabetes in EMEA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
-
Rhea-AI Summary
Dexcom, Inc. (Nasdaq: DXCM) has announced the launch of the Dexcom G7 Continuous Glucose Monitoring (CGM) System, which now connects with the t:slim X2 insulin pump by Tandem Diabetes Care in countries across Europe and in South Africa. The system combines the power and accuracy of Dexcom G7 with the discretion of the Tandem t:slim X2. Dexcom is recognized as the most clinically studied CGM brand with AID capabilities, with more than 1 million patient years of cumulative use. New results from the COMISAIR seven-year follow up show significant and continued reduction of HbA1c as well as a lower risk of the development or progression of diabetic retinopathy associated with the use of real-time CGM by people with Type 1 diabetes. Dexcom G7 is the fastest CGM connected to the t:slim X2 insulin pump, with a 30-minute sensor warmup time, and offers industry-leading remote monitoring capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
DexCom, Inc. (DXCM) expects significant revenue growth in 2023, with unaudited revenue for the fourth quarter projected to be at least $1.030 billion, a 26% increase over the same period in 2022. The company anticipates total revenue for fiscal 2023 to be approximately $3.62 billion, a 24% increase over 2022. DexCom also announced the submission of Stelo, a new glucose sensor for people with type 2 diabetes who do not use insulin, to the U.S. FDA for review, with an expected launch in the U.S. in summer 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.56%
Tags
Rhea-AI Summary
DexCom, Inc. (NASDAQ:DXCM) will present an update at the 42nd annual J.P. Morgan Healthcare Conference on January 8, 2024. The live presentation by Kevin Sayer, Chairman, President, and CEO, will be webcast and archived on the Dexcom Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
-
Rhea-AI Summary
Synchron (SYN) announces the appointment of Andy Rasdal to its Board of Directors. Rasdal brings over 30 years of experience in developing and commercializing novel medical devices. He has led companies through FDA approval, IPO, and commercialization of innovative products, making him a valuable addition to Synchron's board. His career exposure to over 15 PMAs, particularly leading DexCom through FDA approval and eventual IPO, will be invaluable to Synchron. Rasdal's expertise will be crucial as Synchron moves towards pivotal study launch and eventual commercialization of its implantable brain-computer interface technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
-
Rhea-AI Summary
DexCom, Inc. (Nasdaq: DXCM) announced the Dexcom G7 Continuous Glucose Monitoring (CGM) System now connects with the t:slim X2™ insulin pump by Tandem Diabetes Care in the United States, marking the first AID integration with the Dexcom G7 CGM, the world’s most accurate CGM system. The clinically meaningful health outcomes that result from using the t:slim X2 insulin pump with Control-IQ technology are proven only when the system is connected to Dexcom CGM technology. The COMISAIR seven-year follow up showed significant and continued reduction of HbA1c as well as a lower risk of the development or progression of diabetic retinopathy associated with the use of real-time CGM by people with Type 1 diabetes. Additionally, the COMISAIR seven-year follow up demonstrated further substantial reduction in HbA1c when Dexcom CGM is connected to the Tandem t:slim X2 insulin pump with Control-IQ technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
Rhea-AI Summary
Dexcom, Inc. (Nasdaq: DXCM) announces the Dexcom G7 Continuous Glucose Monitoring (CGM) System now connects with the t:slim X2 insulin pump by Tandem Diabetes Care in the United States, marking the first AID integration with the Dexcom G7 CGM. Dexcom G7 is the smallest, most accurate CGM system currently connected to the t:slim X2 insulin pump. The launch of Dexcom G7 and the Tandem t:slim X2 insulin pump further strengthens Dexcom’s position as the world’s most connected CGM.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
FAQ
What is the current stock price of DexCom (DXCM)?
The current stock price of DexCom (DXCM) is $80.04 as of December 20, 2024.
What is the market cap of DexCom (DXCM)?
The market cap of DexCom (DXCM) is approximately 30.6B.
What does DexCom, Inc. specialize in?
DexCom, Inc. specializes in continuous glucose monitoring (CGM) systems for diabetic patients.
When was DexCom, Inc. founded?
DexCom, Inc. was founded in 1999.
What are some of DexCom's key products?
Key products include the Dexcom G6 and Dexcom G7 CGM systems.
How do DexCom's CGM systems benefit diabetic patients?
DexCom's CGM systems provide real-time glucose readings, helping patients and clinicians better manage diabetes.
What recent achievements has DexCom made?
Recent achievements include international market expansion and continuous product enhancements.
How is DexCom integrating its CGM systems with other technologies?
DexCom is integrating its CGM systems with insulin pumps from Insulet and Tandem for automatic insulin delivery.
What is the significance of DexCom's strategic partnerships?
Strategic partnerships enhance DexCom's market presence and technological capabilities.
What is DexCom's approach to innovation?
DexCom is committed to innovation, focusing on research and development to advance diabetes management.
How does DexCom support the community?
DexCom empowers patients, caregivers, and clinicians by delivering effective diabetes management solutions.
What financial trends are seen in DexCom's performance?
DexCom has shown robust growth with increasing revenues and strong market performance.
DexCom, Inc.
Nasdaq:DXCM
DXCM Rankings
DXCM Stock Data
30.65B
389.05M
0.32%
97.12%
2.33%
Medical Devices
Surgical & Medical Instruments & Apparatus
United States of America
SAN DIEGO